SSTR3 Inhibitors
1 drugsAbout SSTR3
SSTR3 (somatostatin receptor 3) is a G protein-coupled receptor that binds the hormone somatostatin, transmitting signals into cells and influencing various physiological processes.
SSTR3 is the target of the FDA-approved drug SIGNIFOR (pasireotide), highlighting its therapeutic potential, though no genetic evidence currently links SSTR3 directly to specific diseases.
SIGNIFOR, a small molecule, is the only approved drug targeting SSTR3, developed by RECORDATI RARE for a single indication classified as 'other'.
Top SSTR3 Drugs
RECORDATI RARE is the only company with an approved drug targeting SSTR3.
Low competition suggests a high barrier to entry or limited perceived market opportunity for SSTR3-targeted therapies.
SSTR3 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SSTR3, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for developing antibody or peptide-based therapeutics.
SSTR3 Clinical Trials 53 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SSTR3. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 9 | 1 | 0 | 90% |
| Phase 2 | 29 | 15 | 11 | 3 | 58% |
| Phase 3 | 8 | 8 | 0 | 0 | 100% |
| Phase 4 | 6 | 4 | 1 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
SSTR3 Drug Approval Timeline (2012 - 2012)
The first and only drug targeting SSTR3, SIGNIFOR, was approved in 2012.
The lack of recent approvals indicates a potentially saturated market or challenges in developing new SSTR3-targeted drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 32 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SSTR3. A trial counts if an approved drug acting on SSTR3 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.